Scholars Central

Conference abstractPublished 10 Aug 2017

Some considerations about biosimilar safety

Authors: Samer M Al-Hulu

Al-Qasim Green University, Iraq

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Statement of the Problem: Biosimilar safety is an important step to be approved. Biosimilar safety is related with the adverse drug reactions as a result of their pharmacological actions and immunogenicities. The purpose of this study is to describe some considerations about biosimilar safety such as naming, immunogenicity, manufacturing, pharmacovigilance, interchangeability, labeling, preclinical studies, clinical studies and post-approval studies. Methodology & Theoretical Orientation: Naming of biosimilar is an important step to differentiate biosimilar from the reference product as a part of safety. Biosimlars are proteins having capacity of inducing immune response that may be humoral or cellular. Small manufacturing alterations in the source materials or production process of any biologic product may lead to changes in molecular structure and potentially its biologic effects. Pharmacovigilance planning include efforts beyond post marketing spontaneous reporting and designed for enhancing and expedite the biosimilar manufacturerâÂ?Â?s acquisition of safety information. Biosimilars, to be approved interchangeable, it must meet a higher standard by producing the same clinical result as the reference product in any given patient. The labeling is important to decide whether a specific adverse event/safety issue for biosimilar is already identified as a risk or could be a new potential safety issue. Preclinical studies used animal models to preliminarily assess toxicity, including immunogenicity. Clinical studies include an assessment of immunogenicity and PK or pharmacodynamics (PD). Finally, the need for post-approval studies to establish efficacy in indications was not studied during the approval process and long-term safety studies. Findings: Biosimilar is a new pharmaceutical product and its safety approval is very important. Conclusion & Significance: Naming of biosimilar is an important step for safety and immunogenicity study is important for safety assessment. Biosimilars, to be approved interchangeable, must meet a higher standard and preclinical studies, clinical studies, postapproval studies, must be achieved. Recommendations: Reaching to unified name, standard definition for biosimilar and close guideline and demonstration of other aspects about biosimilar safety is recommended.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • BylineArticles whose byline prints “Samer M Al-Hulu”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels